The Comparison of Plasma and Cerebrospinal Fluid R(−)- and S(+)-Flurbiprofen Concentration After Intravenous Injection of Flurbiprofen Axetil in Human Subjects

Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (−)- and S (+)-flu...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 12; p. 646196
Main Authors Yao, Han, Luo, Xingxian, Zhang, Hong, An, Haiyan, Feng, Wanyu, Feng, Yi
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 30.04.2021
Subjects
Online AccessGet full text
ISSN1663-9812
1663-9812
DOI10.3389/fphar.2021.646196

Cover

Abstract Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (−)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil. Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5–50 min) after subarachnoid puncture and before actual spinal anesthesia. R (−)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography–tandem mass spectrometry. Results: R (−)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46–34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (−)-flurbiprofen concentration was significantly higher in plasma at all time points ( p < 0.05) except at 30 or 40 min, and lower in CSF at all time points ( p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (−)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC 0–50 for R (−)-flurbiprofen was larger in plasma and smaller in CSF ( p < 0.05 for both), and accordingly smaller CSF/plasma AUC 0–50 ratio ( p < 0.05). There was a positive correlation between R (−)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = −0.250, p = 0.037), but not R (−)-flurbiprofen. Conclusion: Distribution of R (−)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (−)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen.
AbstractList Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (-)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil. A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5-50 min) after subarachnoid puncture and before actual spinal anesthesia. R (-)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography-tandem mass spectrometry. R (-)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46-34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (-)-flurbiprofen concentration was significantly higher in plasma at all time points ( < 0.05) except at 30 or 40 min, and lower in CSF at all time points ( < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (-)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC for R (-)-flurbiprofen was larger in plasma and smaller in CSF ( < 0.05 for both), and accordingly smaller CSF/plasma AUC ratio ( < 0.05). There was a positive correlation between R (-)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, < 0.001) as well as in CSF (r = 0.718, < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = -0.250, = 0.037), but not R (-)-flurbiprofen. Distribution of R (-)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (-)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen.
Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (−)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil. Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5–50 min) after subarachnoid puncture and before actual spinal anesthesia. R (−)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography–tandem mass spectrometry. Results: R (−)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46–34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (−)-flurbiprofen concentration was significantly higher in plasma at all time points ( p < 0.05) except at 30 or 40 min, and lower in CSF at all time points ( p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (−)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC 0–50 for R (−)-flurbiprofen was larger in plasma and smaller in CSF ( p < 0.05 for both), and accordingly smaller CSF/plasma AUC 0–50 ratio ( p < 0.05). There was a positive correlation between R (−)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = −0.250, p = 0.037), but not R (−)-flurbiprofen. Conclusion: Distribution of R (−)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (−)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen.
Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (-)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil. Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5-50 min) after subarachnoid puncture and before actual spinal anesthesia. R (-)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography-tandem mass spectrometry. Results: R (-)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46-34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (-)-flurbiprofen concentration was significantly higher in plasma at all time points (p < 0.05) except at 30 or 40 min, and lower in CSF at all time points (p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (-)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC0-50 for R (-)-flurbiprofen was larger in plasma and smaller in CSF (p < 0.05 for both), and accordingly smaller CSF/plasma AUC0-50 ratio (p < 0.05). There was a positive correlation between R (-)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = -0.250, p = 0.037), but not R (-)-flurbiprofen. Conclusion: Distribution of R (-)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (-)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen.Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (-)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil. Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5-50 min) after subarachnoid puncture and before actual spinal anesthesia. R (-)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography-tandem mass spectrometry. Results: R (-)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46-34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (-)-flurbiprofen concentration was significantly higher in plasma at all time points (p < 0.05) except at 30 or 40 min, and lower in CSF at all time points (p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (-)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC0-50 for R (-)-flurbiprofen was larger in plasma and smaller in CSF (p < 0.05 for both), and accordingly smaller CSF/plasma AUC0-50 ratio (p < 0.05). There was a positive correlation between R (-)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = -0.250, p = 0.037), but not R (-)-flurbiprofen. Conclusion: Distribution of R (-)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (-)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen.
Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (−)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil.Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5–50 min) after subarachnoid puncture and before actual spinal anesthesia. R (−)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography–tandem mass spectrometry.Results: R (−)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46–34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (−)-flurbiprofen concentration was significantly higher in plasma at all time points (p < 0.05) except at 30 or 40 min, and lower in CSF at all time points (p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (−)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC0–50 for R (−)-flurbiprofen was larger in plasma and smaller in CSF (p < 0.05 for both), and accordingly smaller CSF/plasma AUC0–50 ratio (p < 0.05). There was a positive correlation between R (−)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = −0.250, p = 0.037), but not R (−)-flurbiprofen.Conclusion: Distribution of R (−)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (−)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen.
Author Yao, Han
Feng, Yi
Zhang, Hong
Luo, Xingxian
An, Haiyan
Feng, Wanyu
AuthorAffiliation 1 Department of Anesthesiology, Peking University People’s Hospital, Beijing , China
2 Department of Pharmacy, Peking University People’s Hospital, Beijing , China
AuthorAffiliation_xml – name: 2 Department of Pharmacy, Peking University People’s Hospital, Beijing , China
– name: 1 Department of Anesthesiology, Peking University People’s Hospital, Beijing , China
Author_xml – sequence: 1
  givenname: Han
  surname: Yao
  fullname: Yao, Han
– sequence: 2
  givenname: Xingxian
  surname: Luo
  fullname: Luo, Xingxian
– sequence: 3
  givenname: Hong
  surname: Zhang
  fullname: Zhang, Hong
– sequence: 4
  givenname: Haiyan
  surname: An
  fullname: An, Haiyan
– sequence: 5
  givenname: Wanyu
  surname: Feng
  fullname: Feng, Wanyu
– sequence: 6
  givenname: Yi
  surname: Feng
  fullname: Feng, Yi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33995057$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1u1DAQxyNUREvpA3BBPm6FsvgjcZIL0mpF6UqVQLScLcced71K7OAkVXkDzrwBr8aT4E1a1EXCB3s8H7-_NDMvkyPnHSTJa4KXjJXVO9NtZVhSTMmSZ5xU_FlyQjhnaVUSevTEPk7O-n6H42FVxXj2Ijlm0cpxXpwkv262gNa-7WSwvXfIG_S5kX0rkXQarSFAHXzfWScbdNGMVqMvi98_fp6nU_x68fY8je5Q2y54Ay6inAI3BDnYSFuZAQLa7P934PzYR3sHaopFpYPK1T0MtkHWocuxlQ5dj_U-tX-VPDey6eHs4T1Nvl58uFlfplefPm7Wq6tUZTwfUqBYqlqVUtd5TTijBjQvaB5vUFhLTTIw2ijAhaxyXhaygCzXWa1JTmOQnSabmau93Iku2FaG78JLKyaHD7dChsGqBkRR1pyaCK1Ine2FGY16siqM5EQqElnvZ1Y31i3ouSPNAfQw4uxW3Po7EceFGeYRsHgABP9thH4Qre0VNI10ENsoaE7LjBE8pb55qvVX5HHGMaGYE1ScZB_ACGWHaT5R2jaCYLFfKDEtlNgvlJgXKlaSfyof4f-v-QOprtOP
CitedBy_id crossref_primary_10_1021_acsnano_4c01245
crossref_primary_10_1002_chir_23531
crossref_primary_10_2147_JPR_S399454
crossref_primary_10_1016_j_jddst_2024_105407
Cites_doi 10.1046/j.1471-4159.2000.0742094.x
10.1016/0006-2952(88)90762-9
10.2174/138920009789895480
10.11669/cpj.2013.13.014
10.1111/j.1365-2125.2010.03720.x
10.1097/00000542-200603000-00005
10.1016/j.apmr.2011.05.009
10.1002/jps.2600770805
10.1016/0014-2999(94)90247-x
10.1016/0006-2952(91)90039-8
10.1136/rapm-2019-100700
10.1007/bf00266343
10.1038/sj.clpt.6100304
10.1371/journal.pone.0010628
10.1002/ddr.21314
10.1111/j.1365-2125.1994.tb04295.x
10.3390/molecules180910747
10.1007/s00228-003-0574-6
10.1096/fj.00-0130fje10.1096/fasebj.15.1.2
10.1002/brb3.1290
10.1111/j.1365-2125.1992.tb04054.x
10.1055/s-0031-1300446
10.5414/CP203092
10.1016/j.pharmthera.2005.02.004
10.1186/1471-2474-10-127
10.1016/0169-409X(95)00123-O
10.1016/j.pbb.2008.06.008
10.1038/35068566
10.1016/j.asjsur.2017.01.002
10.2165/00003088-200645070-00008
10.1111/j.1365-2125.2007.02846.x
10.2147/JPR.S176475
10.1016/0024-3205(94)00555-9
ContentType Journal Article
Copyright Copyright © 2021 Yao, Luo, Zhang, An, Feng and Feng.
Copyright © 2021 Yao, Luo, Zhang, An, Feng and Feng. 2021 Yao, Luo, Zhang, An, Feng and Feng
Copyright_xml – notice: Copyright © 2021 Yao, Luo, Zhang, An, Feng and Feng.
– notice: Copyright © 2021 Yao, Luo, Zhang, An, Feng and Feng. 2021 Yao, Luo, Zhang, An, Feng and Feng
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fphar.2021.646196
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
CrossRef

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Yao et al
EISSN 1663-9812
ExternalDocumentID oai_doaj_org_article_78b62f0da91b4e20a3232fa97fa61ac1
PMC8120306
33995057
10_3389_fphar_2021_646196
Genre Journal Article
GrantInformation_xml – fundername: National Key Research and Development Program of China
  grantid: 2018YFC2001905
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
RNS
RPM
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c465t-e20acbc8adb5b1632fed6725ed6ec0dad14efdfce07a95687a7e45d4bd152d143
IEDL.DBID M48
ISSN 1663-9812
IngestDate Wed Aug 27 01:30:30 EDT 2025
Thu Aug 21 14:14:35 EDT 2025
Fri Sep 05 06:46:49 EDT 2025
Thu Jan 02 22:56:09 EST 2025
Tue Jul 01 03:27:57 EDT 2025
Thu Apr 24 22:51:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords S(+)-flurbiprofen
R(-)-flurbiprofen
plasma
flurbiprofen axetil
cerebrospinal fluid
Language English
License Copyright © 2021 Yao, Luo, Zhang, An, Feng and Feng.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c465t-e20acbc8adb5b1632fed6725ed6ec0dad14efdfce07a95687a7e45d4bd152d143
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Yoseph Caraco, Hadassah Medical Center, Israel
This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology
Mojca Kržan, University of Ljubljana, Slovenia
These authors have contributed equally to this work.
Reviewed by: Andrei Medvedovici, University of Bucharest, Romania
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2021.646196
PMID 33995057
PQID 2528431006
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_78b62f0da91b4e20a3232fa97fa61ac1
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8120306
proquest_miscellaneous_2528431006
pubmed_primary_33995057
crossref_citationtrail_10_3389_fphar_2021_646196
crossref_primary_10_3389_fphar_2021_646196
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-04-30
PublicationDateYYYYMMDD 2021-04-30
PublicationDate_xml – month: 04
  year: 2021
  text: 2021-04-30
  day: 30
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in pharmacology
PublicationTitleAlternate Front Pharmacol
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Buvanendran (B3) 2006; 104
Matoga (B19) 1999; 49
Zhang (B35) 2007; 64
Kumpulainen (B15) 2010; 70
Sozio (B27) 2013; 18
Wang (B30) 2009; 10
Burian (B2) 2005; 107
Wang (B31) 2019; 9
Mannila (B18) 2006; 45
Tegeder (B29) 2001; 15
Neugebauer (B23) 1995; 275
Sugimoto (B28) 2016; 77
Bishay (B1) 2010; 5
Gulcicek (B12) 2018; 41
Muller (B22) 1991; 42
Ortiz (B25) 2008; 91
Samad (B26) 2001; 410
Ye (B32) 2013; 48
Ohmukai (B24) 1996; 20
Jamali (B13) 1988; 77
Knadler (B14) 1992; 33
Elbaz (B6) 2011; 92
Malmberg (B17) 1994; 256
Memtsoudis (B21) 2019; 44
Debi (B5) 2009; 10
B8
Zhang (B33) 2017; 55
Lee (B16) 2003; 58
Evans (B7) 1992; 42
Geisslinger (B10); 37
Zhang (B34) 2018; 11
Geisslinger (B11) 2000; 74
Geisslinger (B9); 54
Caldwell (B4) 1988; 37
Mehta (B20) 2008; 83
References_xml – volume: 74
  start-page: 2094
  year: 2000
  ident: B11
  article-title: Inhibition of Noxious Stimulus-Induced Spinal Prostaglandin E2 Release by Flurbiprofen Enantiomers
  publication-title: J. Neurochem.
  doi: 10.1046/j.1471-4159.2000.0742094.x
– volume: 37
  start-page: 105
  year: 1988
  ident: B4
  article-title: The Metabolic Chiral Inversion and Dispositional Enantioselectivity of the 2-arylpropionic Acids and Their Biological Consequences
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/0006-2952(88)90762-9
– volume: 10
  start-page: 781
  year: 2009
  ident: B30
  article-title: Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and its Clinical Significance
  publication-title: Cdm
  doi: 10.2174/138920009789895480
– volume: 48
  start-page: 1099
  year: 2013
  ident: B32
  article-title: Establishment of Stereospecific Assay of Flurbiprofen by High-Performance Liquid-Chromatographic Tandem-Mass Spectrometry and its Application to Pharmacokinetic Study
  publication-title: Chin. Pharm. J.
  doi: 10.11669/cpj.2013.13.014
– volume: 70
  start-page: 557
  year: 2010
  ident: B15
  article-title: Plasma and Cerebrospinal Fluid Pharmacokinetics of Flurbiprofen in Children
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.2010.03720.x
– volume: 104
  start-page: 403
  year: 2006
  ident: B3
  article-title: Upregulation of Prostaglandin E2and Interleukins in the Central Nervous System and Peripheral Tissue during and after Surgery in Humans
  publication-title: Anesthesiol.
  doi: 10.1097/00000542-200603000-00005
– volume: 92
  start-page: 1618
  year: 2011
  ident: B6
  article-title: Sex and Body Mass Index Correlate with Western Ontario and McMaster Universities Osteoarthritis Index and Quality of Life Scores in Knee Osteoarthritis
  publication-title: Arch. Phys. Med. Rehabil.
  doi: 10.1016/j.apmr.2011.05.009
– volume: 77
  start-page: 666
  year: 1988
  ident: B13
  article-title: Stereoselective Pharmacokinetics of Flurbiprofen in Humans and Rats
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.2600770805
– volume: 256
  start-page: 205
  year: 1994
  ident: B17
  article-title: Antinociception Produced by Spinal Delivery of the S and R Enantiomers of Flurbiprofen in the Formalin Test
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/0014-2999(94)90247-x
– volume: 42
  start-page: 799
  year: 1991
  ident: B22
  article-title: Protein Binding of Indomethacin in Human Cerebrospinal Fluid
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/0006-2952(91)90039-8
– volume: 44
  start-page: 934
  year: 2019
  ident: B21
  article-title: Risk Factors for Postoperative Delirium in Patients Undergoing Lower Extremity Joint Arthroplasty: a Retrospective Population-Based Cohort Study
  publication-title: Reg. Anesth. Pain Med.
  doi: 10.1136/rapm-2019-100700
– volume: 42
  start-page: 237
  year: 1992
  ident: B7
  article-title: Enantioselective Pharmacodynamics and Pharmacokinetics of Chiral Non-steroidal Anti-inflammatory Drugs
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/bf00266343
– volume: 83
  start-page: 430
  year: 2008
  ident: B20
  article-title: Intravenous Parecoxib Rapidly Leads to COX-2 Inhibitory Concentration of Valdecoxib in the Central Nervous System
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/sj.clpt.6100304
– volume: 5
  start-page: e10628
  year: 2010
  ident: B1
  article-title: R-flurbiprofen Reduces Neuropathic Pain in Rodents by Restoring Endogenous Cannabinoids
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0010628
– volume: 77
  start-page: 206
  year: 2016
  ident: B28
  article-title: Topical Anti‐Inflammatory and Analgesic Effects of Multiple Applications of S(+)‐Flurbiprofen Plaster (SFPP) in a Rat Adjuvant‐Induced Arthritis Model
  publication-title: Drug Dev. Res.
  doi: 10.1002/ddr.21314
– volume: 37
  start-page: 392
  ident: B10
  article-title: Stereoselective Disposition of Flurbiprofen in Healthy Subjects Following Administration of the Single Enantiomers
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.1994.tb04295.x
– volume: 18
  start-page: 10747
  year: 2013
  ident: B27
  article-title: New Flurbiprofen Derivatives: Synthesis, Membrane Affinity and Evaluation of In Vitro Effect on β-Amyloid Levels
  publication-title: Molecules
  doi: 10.3390/molecules180910747
– volume: 58
  start-page: 791
  year: 2003
  ident: B16
  article-title: Differences in Flurbiprofen Pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 Genotypes
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/s00228-003-0574-6
– ident: B8
– volume: 15
  start-page: 2
  year: 2001
  ident: B29
  article-title: Inhibition of NF‐KB and AP‐1 Activation by R‐ and S‐flurbiprofen
  publication-title: FASEB j.
  doi: 10.1096/fj.00-0130fje10.1096/fasebj.15.1.2
– volume: 9
  start-page: e01290
  year: 2019
  ident: B31
  article-title: Effect of Flurbiprofen Axetil on Postoperative Delirium for Elderly Patients
  publication-title: Brain Behav.
  doi: 10.1002/brb3.1290
– volume: 275
  start-page: 618
  year: 1995
  ident: B23
  article-title: Antinociceptive Effects of R(-)- and S(+)-flurbiprofen on Rat Spinal Dorsal Horn Neurons Rendered Hyperexcitable by an Acute Knee Joint Inflammation
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 33
  start-page: 369
  year: 1992
  ident: B14
  article-title: Stereoselective Disposition of Flurbiprofen in Normal Volunteers
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.1992.tb04054.x
– volume: 49
  start-page: 477
  year: 1999
  ident: B19
  article-title: Influence of Molecular Lipophilicity on the Diffusion of Arylpropionate Non-steroidal Anti-inflammatory Drugs into the Cerebrospinal Fluid
  publication-title: Arzneimittelforschung
  doi: 10.1055/s-0031-1300446
– volume: 55
  start-page: 875
  year: 2017
  ident: B33
  article-title: Absorption Kinetics of Flurbiprofen Axetil Microspheres in Cerebrospinal Fluid: A Pilot Study
  publication-title: Cp
  doi: 10.5414/CP203092
– volume: 107
  start-page: 139
  year: 2005
  ident: B2
  article-title: COX-dependent Mechanisms Involved in the Antinociceptive Action of NSAIDs at Central and Peripheral Sites
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2005.02.004
– volume: 10
  start-page: 127
  year: 2009
  ident: B5
  article-title: Differences in Gait Patterns, Pain, Function and Quality of Life between Males and Females with Knee Osteoarthritis: a Clinical Trial
  publication-title: BMC Musculoskelet. Disord.
  doi: 10.1186/1471-2474-10-127
– volume: 20
  start-page: 203
  year: 1996
  ident: B24
  article-title: Lipo-NSAID Preparation
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/0169-409X(95)00123-O
– volume: 91
  start-page: 32
  year: 2008
  ident: B25
  article-title: Additive Interaction between Peripheral and Central Mechanisms Involved in the Antinociceptive Effect of Diclofenac in the Formalin Test in Rats
  publication-title: Pharmacol. Biochem. Behav.
  doi: 10.1016/j.pbb.2008.06.008
– volume: 410
  start-page: 471
  year: 2001
  ident: B26
  article-title: Interleukin-1β-mediated Induction of Cox-2 in the CNS Contributes to Inflammatory Pain Hypersensitivity
  publication-title: Nature
  doi: 10.1038/35068566
– volume: 41
  start-page: 264
  year: 2018
  ident: B12
  article-title: Role of Diclofenac Sodium and Paracetamol on Colonic Anastomosis: An Experimental Rodent Model
  publication-title: Asian J. Surg.
  doi: 10.1016/j.asjsur.2017.01.002
– volume: 45
  start-page: 737
  year: 2006
  ident: B18
  article-title: Cerebrospinal Fluid Distribution of Ketoprofen after Intravenous Administration in Young Children
  publication-title: Clin. Pharmacokinet.
  doi: 10.2165/00003088-200645070-00008
– volume: 64
  start-page: 67
  year: 2007
  ident: B35
  article-title: Influence of CYP2C9 and CYP2C19 Genetic Polymorphisms on Pharmacokinetics of Gliclazide MR in Chinese Subjects
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.2007.02846.x
– volume: 11
  start-page: 3061
  year: 2018
  ident: B34
  article-title: Population Pharmacokinetic Modeling of Flurbiprofen, the Active Metabolite of Flurbiprofen Axetil, in Chinese Patients with Postoperative Pain
  publication-title: Jpr
  doi: 10.2147/JPR.S176475
– volume: 54
  start-page: Pl173
  ident: B9
  article-title: Antinociceptive Actions of R(−)-flurbiprofen - a Non-cyclooxygenase Inhibiting 2-arylpropionic Acid - in Rats
  publication-title: Life Sci.
  doi: 10.1016/0024-3205(94)00555-9
SSID ssj0000399364
Score 2.2877097
Snippet Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through...
Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a...
Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 646196
SubjectTerms cerebrospinal fluid
flurbiprofen axetil
Pharmacology
plasma
R(-)-flurbiprofen
S(+)-flurbiprofen
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbhMxELZQT1wQ_4Q_GQlVLdR01-u1s8cQERUkUASt1Jtlr211q-BWaYroG3DmDXg1noQZO02zCMGFyyq79saWv1nPN7L9DSHPK-mlA8_GArgPBgxcMQs0g1VyaHgoPThFPDv8_oPcOxDvDuvDtVRfuCcsywPngdtVQyt5KJxpSis8L0wFHCCYRgUjS9OmwKdoirVgKs3B6HelyMuYEIU1u-H0yKD-Jy9fSQFRg-w5oqTX_yeS-fteyTXnM7lJbixZIx3l3t4i13y8TTanWXb6YofuX52iOtuhm3R6JUh9cYf8gGI6XiUcpCeBToE0fzbUREfHfg5xMaYPwSYms_PO0Y9bP79932ap_NPWy20Gj-e2wwTfPsJfxdxPBJWOMMs4fYv3X5LgK_w-Thu8Uku9N0df_aKb0S7StHhAYdrCqmd3ycHkzf54jy1TM7BWyHrBEIjWtkPjbG2B0vHgnVS8hqtvASxXCh9caH2hDB5IVEZ5UTthHfAFKKzukY14Ev0DQnkRgpONMkVohAKUG87bViqYpUtbWTMgxSVOul3qlmP6jJmG-AWh1QlajdDqDO2AvFi9cppFO_5W-TWCv6qIetvpAVihXlqh_pcVDsizS9PR8H3ioouJHoZc8xoIAK6iQEP3symtmqrwXDEQ5gFRPSPr9aVfErujpAEOvAyjvYf_o_OPyHUcj7xG9phsLObn_glQrYV9mr6qX1_dK_4
  priority: 102
  providerName: Directory of Open Access Journals
Title The Comparison of Plasma and Cerebrospinal Fluid R(−)- and S(+)-Flurbiprofen Concentration After Intravenous Injection of Flurbiprofen Axetil in Human Subjects
URI https://www.ncbi.nlm.nih.gov/pubmed/33995057
https://www.proquest.com/docview/2528431006
https://pubmed.ncbi.nlm.nih.gov/PMC8120306
https://doaj.org/article/78b62f0da91b4e20a3232fa97fa61ac1
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwFLbGuOEGbfx2jMlIaNpgGYmT2M0FQqWiGkhDFazS7iL_skxdOtIOrW_ANW_Aq_EknOOkHUEVV9xESWzHjo_t852c-DuEPI-55QY0W-BAfQSAwEWgAGYEMe9K5iILShH3Dh9_5Eej5MNperpGFuGtmg6crjTtMJ7UqBofXn-dv4EJ_xotTtC3r9zlmURqTxYd8gQMAn6L3AbFxNEWO27Qvl-YURnzpPZtri7Z0k6exH8V8vz7B8o_NNJgg9xtoCTt1bLfJGu2vEd2hzUX9fyAntxsrZoe0F06vGGpnt8nPyGZ9pdRCOnE0SEg6QtJZWlo31ZgLGNMEaxiML4qDP209-v7j_3Ap3_ee7kfwO1KFRj125bwqLJuJ0qa9jD0OH2P1988Cyycn_u_vnxNrZK9azsrxrQoqfcoUFjLMOv0ARkN3p30j4ImXkOgE57OAstCqZXuSqNSBTiPOWu4YCkcrQ6NNFFinXHahkLiLkUhhU1SkygDIAIS44dkvZyU9jGhLHTO8EzI0GWJyCKVMaY1F7B0RypWskPChZxy3ZCZY0yNcQ5GDYo296LNUbR5LdoOebEsclkzefwr81sU_jIjknD7G5PqS97M6Vx0FWcOXgzal-DLxwBPncyEkzySOuqQZ4uhk8OkRU-MLC10ec5SQAXoWoGKHtVDaVlVjJuNAUV3iGgNslZb2illceaJwQGsoQm49T8a_4Tcwf6oHWfbZH1WXdmngL9masd_t9jxc-s3IVQ1LA
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Comparison+of+Plasma+and+Cerebrospinal+Fluid+R%28%E2%88%92%29-+and+S%28%2B%29-Flurbiprofen+Concentration+After+Intravenous+Injection+of+Flurbiprofen+Axetil+in+Human+Subjects&rft.jtitle=Frontiers+in+pharmacology&rft.au=Han+Yao&rft.au=Xingxian+Luo&rft.au=Hong+Zhang&rft.au=Haiyan+An&rft.date=2021-04-30&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=12&rft_id=info:doi/10.3389%2Ffphar.2021.646196&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_78b62f0da91b4e20a3232fa97fa61ac1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon